Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614020 | 1.00 | GNAI3 (0.44) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL6535833 | 1.00 | GNAI3 (0.44) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL19846402 | 0.89 | NOD1 (0.40) | EPHX1NOD1GRIK1GRIK2GPR84 | |
| SCHEMBL28077042 | 0.87 | NOD1 (0.51) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL341674 | 0.87 | NOD1 (0.51) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL1031164 | 0.87 | NOD1 (0.51) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL30775015 | 0.87 | NOD1 (0.51) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL20589912 | 0.86 | NOD1 (0.39) | EPHX1NOD1GRIK1GRIK2GPR84 | |
| SCHEMBL9634471 | 0.85 | NOD1 (0.49) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL9634474 | 0.85 | NOD1 (0.49) | GNAI3GNAO1GNAI1DNM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0799059-B1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-07-31 | — | — | EP | claimed |
| EP-0799059-A1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-10-08 | — | — | EP | claimed |
| WO-1996018372-A2 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0799059-B1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6383814-B1 | AEROSOLIZED SOLUTION INCLUDES BIOLOGICALLY ACTIVE MOLECULE, CATIONIC AMPHIPHILE FOR TRANSPORT OF ACTIVE MOLECULE INTO CELL, AND POLYETHYLENE GLYCOL-PHOSPHATIDYLETHANOLAMINE; GENE THERAPY; ANTISENSE AGENTS | GENZYME CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-20020013282-A1 | CATIONIC AMPHIPILE COMPOSITIONS FOR INTERACELLUAR DELIVERY OF THERAPEUTIC MOLECULES | MARSHALL JOHN (US) | 2002-01-31 | — | — | US | disclosed |
| US-6331524-B1 | ADMINISTERING COMPLEX OF SPERMIDINE CHOLESTEROL CARBAMATE AND POLYNUCLEOTIDE ENCODING RETINOBLASTOMA PROTEIN AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | GENZYME CORPORATION | 2001-12-18 | — | — | US | disclosed |
| EP-1007003-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6071890-A | COMPLEX OF A BIOLOGICALLY ACTIVE MOLECULE SELECTED FROM A PROTEIN, SMALL MOLECULE, NUCLEIC ACIDS WITH A CATIONIC AMPHIPHILE | GENZYME CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0954339-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5948767-A | TRANSPORT OF ACTIVE MATERIAL INTO CELLS; DRUG DELIVERY | GENZYME CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0845981-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5747471-A | DNA, RNA AND ANTISENSE POLYNUCLEOTIDES FOR GENE THERAPY | GENZYME CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998013026-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5719131-A | GENE THERAPY | GENZYME CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998002191-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997046223-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0799059-A1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5650096-A | Cationic amphiphiles for intracellular delivery of therapeutic molecules | GENZYME CORPORATION (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996018372-A2 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013282-A1 | CATIONIC AMPHIPILE COMPOSITIONS FOR INTERACELLUAR DELIVERY OF THERAPEUTIC MOLECULES | ANXA4, ABCB4, SLC43A1 | GNAI3 2106/4885GNAO1 3691/4885GNAI1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.